Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK, April 17, 2025 /PRNewswire/ -- ...
HT-KIT demonstrates significant tumor downregulation and over 80% reduction in KIT expression in preclinical models of GIST and systemic mastocytosis. The therapy targets KIT gene expression at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback